Fast Track vs. Breakthrough Therapy Designation: Understanding the Key Differences
Sponsors developing therapies for serious conditions have four FDA expedited programs available to them. Two of those programs, Fast Track and Breakthrough Therapy, are development-stage designations that shape how a sponsor interacts with FDA long before an NDA or BLA is filed. They are often discussed together, sometimes treated as interchangeable, and just as often confused.
They are not the same. The eligibility bars differ, the evidence they require differs, the timing sweet spots differ, and the FDA engagement they unlock differs. Choosing between them, or sequencing them, is a strategic decision that affects your development plan, your trial design, and the pace at which you can get to a marketing application.
At Only Orphans Cote, we help sponsors secure Fast Track and Breakthrough Therapy designations alongside orphan drug designation and other expedited programs. Led by Dr. Timothy Cote, former Director of FDA's Office of Orphan Products Development, our team knows how each of these programs is evaluated inside the agency and how to position a submission that lands.
What is the Difference Between Fast Track & Breakthrough Therapy Designations?
Both programs exist to expedite the development and review of drugs for serious or life-threatening conditions. The difference is what you have to show FDA to qualify.
Fast Track Designation
Fast Track is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. Whether a condition is "serious" is a matter of judgment, but FDA considers factors such as impact on survival, day-to-day functioning, or the likelihood the condition will progress from a less severe form to a more serious one. FDA has publicly cited AIDS, Alzheimer's, heart failure, cancer, epilepsy, depression, and diabetes as examples of serious conditions.
Filling an unmet medical need means providing a therapy where none exists, or providing a therapy that may be better than what is available. If available therapies already exist, a Fast Track drug must show some advantage over them, such as superior effectiveness, improved effect on serious outcomes, a way to avoid serious side effects, an ability to improve early diagnosis where that changes outcomes, or an ability to address an emerging public health need.
The key point for evidence: Fast Track can be granted on the basis of nonclinical (preclinical) data or clinical data. A sponsor does not need patient data to qualify.
A drug that receives Fast Track designation is eligible for some or all of the following:
- More frequent meetings with FDA to discuss the drug's development plan.
- More frequent written communication from FDA on things like trial design and biomarker use.
- Eligibility for Accelerated Approval and Priority Review if the relevant criteria are met.
- Rolling review, which allows the sponsor to submit completed sections of the BLA or NDA as they are ready, rather than waiting until the full application is complete.
Fast Track designation is requested by the sponsor. The request may be made at the same time as the IND submission, or any time after. FDA responds within 60 days.
Breakthrough Therapy Designation
Breakthrough Therapy designation is for a drug that treats a serious or life-threatening condition and where preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint.
Two things in that definition do heavy work.
"Preliminary clinical evidence." Unlike Fast Track, Breakthrough Therapy requires actual patient data. Preclinical data alone will not qualify.
"Substantial improvement over available therapy on a clinically significant endpoint." A clinically significant endpoint generally refers to one that measures an effect on irreversible morbidity or mortality (IMM) or on symptoms representing serious consequences of the disease. It can also include an effect on an established surrogate endpoint, an effect on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit, an effect on a pharmacodynamic biomarker that strongly suggests a clinically meaningful effect, or a significantly improved safety profile compared to available therapy with evidence of similar efficacy. "Substantial improvement" itself is a judgment call based on the magnitude of the treatment effect and the importance of the clinical outcome. FDA looks for a clear advantage over available therapy.
A drug that receives Breakthrough Therapy designation gets all of the Fast Track features, plus:
- Intensive FDA guidance on an efficient drug development program, beginning as early as Phase 1.
- An organizational commitment involving FDA senior managers.
- A cross-disciplinary project lead on the FDA review team.
- Eligibility for rolling review and priority review.
As Dr. Timothy Cote has put it in describing Breakthrough Therapy, "you get extra love from the FDA."
That extra engagement is the point of the program. Breakthrough Therapy is not just a label; it is a working relationship with senior FDA staff that starts early and continues through approval.
Breakthrough Therapy designation is also requested by the sponsor, though FDA may suggest that a sponsor consider requesting it if the agency believes the program may meet the criteria after reviewing submitted data. FDA responds within 60 days. FDA encourages sponsors to submit the request no later than the end-of-Phase-2 meeting, and generally does not expect Breakthrough Therapy designation requests to be submitted after the original BLA or NDA has already been filed.
The Evidence Bar Is the Central Difference
The clearest way to think about this: Fast Track asks whether your drug has the potential to address an unmet medical need. Breakthrough Therapy asks whether preliminary clinical evidence shows your drug may deliver a substantial improvement over available therapy.
Fast Track is often the right first step. A program with a strong nonclinical package, a serious condition, and a plausible case for unmet medical need can qualify at IND. Breakthrough Therapy sits further down the development path. It generally makes sense once clinical data has surfaced early signals that meaningfully beat what patients currently have access to.
Can a Sponsor Hold Both?
Yes, though the two programs require separate requests. Fast Track and Breakthrough Therapy are administered as separate programs; if you want both, you file for both. Because Breakthrough Therapy conveys all of the Fast Track program features, sponsors granted Breakthrough Therapy often do not need to also request Fast Track. In practice, sponsors commonly obtain Fast Track early, based on nonclinical data, and then pursue Breakthrough Therapy later, once clinical data supports the higher bar.
One important note: if Breakthrough Therapy is denied, the request is not automatically reviewed for Fast Track. A separate Fast Track request must be submitted.
Common Misconceptions
- Neither designation is an approval - Both are development-stage designations. They shape how FDA engages with the program; they do not authorize commercialization.
- Neither designation shortens the review clock on its own - The 10-month standard PDUFA review clock is compressed to 6 months only under Priority Review, which is a separate program at the marketing-application stage. Breakthrough Therapy makes a drug eligible for Priority Review; Fast Track drugs are also eligible if the relevant criteria are met.
- Preclinical data alone will not get you Breakthrough Therapy - The definition requires preliminary clinical evidence. If you are pre-clinical, Fast Track is the program to pursue first.
- A denial of Breakthrough Therapy does not close the door on Fast Track - They are independent programs with independent applications.
Comparison at a Glance
| Feature | Fast Track Designation | Breakthrough Therapy Designation |
|---|---|---|
| Purpose | Facilitate development and expedite review of drugs for serious conditions with unmet medical need | Expedite development and review of drugs for serious/life-threatening conditions where preliminary clinical evidence shows substantial improvement over available therapy |
| Evidence required | Nonclinical or clinical data demonstrating potential to address an unmet medical need | Preliminary clinical evidence of substantial improvement on a clinically significant endpoint over available therapy |
| Stage of development | Any stage after IND, including pre-clinical and early clinical | Typically after early clinical data is available; ideally by end-of-Phase-2 |
| FDA engagement | More frequent meetings and written communication with FDA | All Fast Track features plus intensive guidance from Phase 1, senior manager involvement, cross-disciplinary project lead |
| Rolling review | Yes | Yes |
Who Should I Contact for Consultation on the FDA's Expedited Development Programs?
The right time to think about Fast Track and Breakthrough Therapy is well before you file the request. Both programs work best when the underlying development plan is designed with them in mind: the clinical trial design, the endpoints, the interaction cadence with FDA, and the way the submission is framed.
At Only Orphans Cote, we support sponsors on Fast Track and Breakthrough Therapy submissions alongside our core work on FDA and EMA orphan drug designation and FDA meetings. Our team is led by Dr. Timothy Cote, former Director of FDA's Office of Orphan Products Development, and includes a former FDA OOPD reviewer. That gives us a working understanding of how the agency evaluates expedited program requests and where sponsors most often lose ground on the details.
Our complimentary consultation with Dr. Cote on expedited program submissions includes:
- Eligibility assessment based on your nonclinical and clinical data.
- Regulatory strategy that sequences Fast Track and Breakthrough Therapy alongside orphan drug designation where relevant.
- General orphan regulatory pathway planning.
See our services overview for the broader scope of what we support, or read our earlier blog on expedited programs beyond orphan designation for a wider survey of the four FDA expedited programs.
Conclusion
Fast Track and Breakthrough Therapy are both designed to help sponsors of drugs for serious conditions move faster, but they operate at different points on the development curve. Fast Track is the earlier, more accessible designation, granted on the basis of nonclinical or clinical data and often the first expedited program a sponsor pursues. Breakthrough Therapy requires preliminary clinical evidence of substantial improvement over available therapy, and it unlocks a deeper level of engagement with FDA senior staff and reviewers.
Choosing the right designation, and timing the request correctly, is part of a broader regulatory strategy. Only Orphans Cote helps sponsors think through that strategy and prepare submissions that stand up to FDA review. Contact us to discuss how Fast Track, Breakthrough Therapy, or both may fit into your development plan.
Frequently Asked Questions
1: What is the difference between Fast Track and Breakthrough Therapy Designation?
Fast Track can be granted on the basis of nonclinical or clinical data showing a drug's potential to address an unmet medical need in a serious condition. Breakthrough Therapy requires preliminary clinical evidence that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint. Breakthrough Therapy conveys all Fast Track program features and adds intensive FDA guidance and senior manager involvement.
2: Can a drug receive both Fast Track and Breakthrough Therapy Designation?
Yes, but each is a separate program with a separate application. Because Breakthrough Therapy already conveys all Fast Track features, sponsors with Breakthrough Therapy designation often do not need to separately hold Fast Track. In practice, sponsors commonly obtain Fast Track early on nonclinical data, then pursue Breakthrough Therapy once clinical data supports the higher bar.
3: When should a sponsor request Fast Track or Breakthrough Therapy Designation?
A Fast Track request can be submitted concurrently with the IND, or at any point after. Breakthrough Therapy requests are ideally submitted no later than the end-of-Phase-2 meeting so the sponsor can benefit from the intensive FDA engagement the program provides during clinical development. FDA generally does not expect Breakthrough Therapy requests after an original BLA or NDA has been filed.
4: How long does the FDA take to respond to a Fast Track or Breakthrough Therapy request?
FDA responds to both Fast Track and Breakthrough Therapy designation requests within 60 days of receipt.
5: Does Fast Track or Breakthrough Therapy Designation shorten FDA review time?
Neither designation directly compresses the marketing application review clock. Standard review is 10 months and Priority Review is 6 months under PDUFA. Breakthrough Therapy makes a product eligible for Priority Review; Fast Track drugs are also eligible for Priority Review if the relevant criteria are met. Both designations, however, allow rolling review, which lets sponsors submit completed sections of an NDA or BLA as they are ready.
6: If the FDA denies my Breakthrough Therapy Designation request, will they consider it for Fast Track?
No. Fast Track and Breakthrough Therapy designations are separate programs and require separate requests. A denial of one does not trigger automatic review for the other.
Accelerate Your Orphan Drug Strategy
Only Orphans Cote helps sponsors secure orphan drug designation faster. Contact us today to schedule a consultation with Dr. Tim Cote and our team.
